CLEAN COPY OF AMENDMENTS

In the Claims:

Please amend the claims as follows:

1. (Amended) A biphasic injectable composition comprising:

solid polymer particles, wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.

2. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

3. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are made from at least two of micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

4. (Amended) The composition of Claim 1, wherein the liquid carrier substrate phase is selected from polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.

5. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles comprise micronized expanded polytetrafluoroethelene ("e-PTFE") particles.

7. (Amended) The composition of Claim 1, wherein the liquid carrier substrate phase is polyvinylpyrrolidone.

8. (Amended) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

9. (Amended) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Amended) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Amended) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles comprise e-PTFE; and

the carrier substrate comprises polyvinylpyrrolidone.

13. (Amended) The composition of Claim 12 wherein the e-PTFE and the PVP are combined at a ratio of approximately 3:2 polyvinylpyrrolidone to e-PTFE by weight.

14. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles comprise micronized polydioxanone particles ranging in size from approximately 65 to 1000 micrometers.

15. (Amended) A method for tissue augmentation comprising:

injecting a biphasic injectable composition comprising:

solid polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.

16. (Amended) The method of Claim 15, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

17. (Amended) The method of Claim 15, wherein the liquid carrier substrate [redacted] is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.